Gper mediated action of estrogen in edometrial receptivity of women with high serum estradiol level on hCG day

2016 ◽  
Vol 106 (3) ◽  
pp. e13
Author(s):  
Y. Shi ◽  
C. Fang ◽  
R. Huang ◽  
X. Liang
Keyword(s):  
High Serum ◽  
Estradiol Level ◽  
Serum Estradiol ◽  
Serum Estradiol Level ◽  
Mediated Action

scholarly journals Could Obesity be a Triggering Factor for Endometrial Tubal Metaplasia to be a Precancerous Lesion?

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Ayman M. El-Saka ◽  
Yomna A. Zamzam ◽  
Yosra A. Zamzam ◽  
Ayman El-Dorf
Keyword(s):  
Endometrial Carcinoma ◽  
Endometrial Hyperplasia ◽  
High Serum ◽  
Estradiol Level ◽  
Serous Carcinoma ◽  
Serum Estradiol ◽  
Serum Estradiol Level ◽  
Group 3 ◽  
The Impact ◽  
Group 1

Background & Aims. Endometrial tubal metaplasia (ETM) is mostly described in conjunction with unopposed estrogen levels, and its association with endometrial hyperplasia and endometrial carcinoma (EC) is striking. Obesity is a risk factor for endometrial hyperplasia and EC development. The aim of this study is to investigate the impact of BMI and serum estradiol level on expression of PAX-2, H-TERT, P16, Ki-67, and P53 in studied ETM in reference to benign endometrium and EC. Methods. The study was conducted on the following groups: group (1) consists of 57 cases that had endometrial biopsies with histologically demonstrable ETM (typical or atypical) and all were subjected to serum estradiol levelling and body mass index (BMI) evaluation; group (2) had adjacent benign endometrial tissue as control; group (3) consists of 52 cases of conventional endometrial carcinoma and 16 serous carcinoma paraffin blocks which were collected and reevaluated. All included groups were immunostained for PAX-2, H-TERT, p16, ki67, and p53. Results. The relation between BMI and serum estradiol level in group 1 and PAX-2, H-TERT, P16, and p53 was statistically significant, while their relation with atypia and ki67 expression was insignificant. Twenty-three ETM cases (40.4%) out of group 1 were all (100%) obese, 87% had high serum estradiol level, and 73.9% were postmenopausal and had a similar immunohistochemical profile as EC cases (group 3). Conclusions. The presence of ETM regardless of the histologic atypia in obese postmenopausal patients with high serum estradiol level is an alarming sign. This implies that ETM might not be as benign as generally accepted, as under certain clinical conditions, it may turn into a potential premalignant lesion.

scholarly journals Feminizing Adrenal Carcinoma Presenting with Heart Failure and Ventricular Tachycardia

2012 ◽  
Vol 2012 ◽  
pp. 1-5
Author(s):  
Anjana Harnoor ◽  
R. Lee West ◽  
Fiona J. Cook
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Ventricular Arrhythmia ◽  
High Serum ◽  
Estradiol Level ◽  
Adrenal Tumors ◽  
Adrenal Carcinoma ◽  
Serum Estradiol ◽  
Serum Estradiol Level ◽  
Very High

We present a case of feminizing adrenal carcinoma with severe elevation in serum estradiol and otherwise unexplained congestive heart failure with ventricular arrhythmia and review the literature on feminizing adrenal tumors and the potential relationship between estrogen and cardiac problems. A 54-year-old man presented with congestive heart failure and ventricular arrhythmia. Imaging revealed a large adrenal mass. Hormonal evaluation revealed a very high serum level of estradiol, elevated DHEA-sulfate and androstenedione, and lack of cortisol suppression on a low-dose overnight dexamethasone suppression test. The patient underwent a left adrenalectomy with subsequent normalization of serum estradiol. Surgical pathology examination established adrenocortical carcinoma MacFarlane stage II. Upon 15-month followup, the patient continued to have a normal serum estradiol level, his cardiac function was significantly improved, and he had no further episodes of ventricular arrhythmia. To the best of our knowledge, the serum estradiol level that was detected in our case is the highest that has been reported. Further, we hypothesize that the very high serum concentration of estradiol in our case may have played a role in his cardiac presentation with congestive heart failure and arrhythmia, particularly as these problems resolved with normalization of his serum estradiol level.

scholarly journals Natural phenolic acids may increase serum estradiol level in ovariectomized rats.

2009 ◽  
Vol 56 (3) ◽  
Author(s):  
Maria Zych ◽  
Joanna Folwarczna ◽  
Henryk I Trzeciak
Keyword(s):  
Total Cholesterol ◽  
Body Mass ◽  
Phenolic Acids ◽  
Mass Gain ◽  
Estradiol Level ◽  
Ovariectomized Rats ◽  
Serum Estradiol ◽  
Chlorogenic Acids ◽  
Serum Estradiol Level ◽  
Cholesterol Levels

Natural phenolic acids are commonly present in plants consumed in the diet. Recently we have observed that different natural phenolic acids exert differential effects on the body mass gain in ovariectomized and non-ovariectomized female rats. The aim of the present study was to investigate the effects of ferulic, caffeic, p-coumaric and chlorogenic acids on serum estradiol and total cholesterol levels in ovariectomized and non-ovariectomized rats. The experiments were carried out on 3-month old female Wistar Cmd:(WI)WU rats, divided into following groups (n=8 in each group): non-ovariectomized control rats and non-ovariectomized rats receiving ferulic, caffeic, p-coumaric or chlorogenic acids, sham-operated control rats, ovariectomized control rats and ovariectomized rats receiving the same phenolic acids. The phenolic acids were administered at a dose of 10 mg/kg p.o. daily for 4 weeks. Serum estradiol and total cholesterol levels on the next day after the last administration of the phenolic acids were examined. The phenolic acids did not affect serum estradiol or total cholesterol levels in non-ovariectomized rats. In ovariectomized rats, caffeic acid and to a lesser extent p-coumaric acid increased serum estradiol level, which effect correlated with a decreased body mass gain. All the phenolic acids decreased serum cholesterol level in ovariectomized rats. Concluding, the anti-obesity activity of some phenolic acids may be, at least partially, connected with estrogenic pathways.

scholarly journals The Relationship Between Musculoskeletal Pains, Serum Estradiol Level and Climacteric Symptoms in Postmenopausal Women

2020 ◽  
Author(s):  
Neda Mohamadzade ◽  
Shahideh Jahanian Sadatmahalleh ◽  
Saeideh Ziaei ◽  
Narges Zaeemzadeh ◽  
Anoshirvan Kazemnejad
Keyword(s):  
Postmenopausal Women ◽  
Musculoskeletal Pain ◽  
Rating Scale ◽  
Personal Data ◽  
Cross Sectional Study ◽  
Estradiol Level ◽  
Serum Estradiol ◽  
Climacteric Symptoms ◽  
Cross Sectional ◽  
Serum Estradiol Level

Abstract Background: Due to the decrease of estrogen levels in postmenopausal females, menopause can be associated with musculoskeletal pains. This study was designed to assess the possible association between musculoskeletal pains, serum estradiol level, and climacteric symptoms in postmenopausal women.Methods: This cross-sectional study was conducted on 307 postmenopausal females selected by convenience sampling method. Data collection procedure lasted from October 2016 to September 2018. The required data were collected using the Menopause Rating Scale (MRS), Örebro Musculoskeletal Pain Questionnaire (ÖMPQ), and a questionnaire containing personal data. The blood sample was taken to measure the estradiol level. Results: There was a direct relationship between musculoskeletal pains and menopause symptoms (p<0.001), age (p=0.03), parity (p=0.01), and BMI (p=0.03) and an indirect association between musculoskeletal pain and marriage age (p=0.009), age of first pregnancy (0.017), estradiol level (p<0.001) and education level (p=0.002). The regression analysis results showed that menopause symptoms were the strongest predictor of musculoskeletal pains among all the variables.Conclusions: The findings of the present study showed that although various parameters are associated with musculoskeletal pains, climacteric symptoms are the most important predictive parameters of musculoskeletal pains.

Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene

2002 ◽  
Vol 57 (5) ◽  
pp. 295-296
Author(s):  
Steven R. Cummings ◽  
Tu Duong ◽  
Emily Kenyon ◽  
Jane A. Cauley ◽  
Malcolm Whitehead ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estradiol Level ◽  
Serum Estradiol ◽  
Serum Estradiol Level
Sign in / Sign up

Export Citation Format

Share Document